Global CNS Treatment And Therapy Market Is Projected To Reach USD 218.8 Billion By 2035 | CAGR of 5.1%

Global CNS Treatment And Therapy Market Is Projected To Reach USD 218.8 Billion By 2035

According to a Research Report Published by Spherical Insights & Consulting, The Global CNS Treatment and Therapy Market Size is Expected to Grow from USD 126.6 Billion in 2024 to USD 218.8 Billion by 2035, at a CAGR of 5.1% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the " Global CNS Treatment and Therapy Market Size, Share, and COVID-19 Impact Analysis, By Drug (Biologics and Non Biologics), By Drug Class (Antidepressant, Analgesics, Immunomodulators, Interferons, Decarboxylase Inhibitors, and Others), By Disease (Neurovascular Disease, Degenerative Disease, Infectious Disease, Mental Health, and Others), By Distribution Channel (Hospital Based Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Detailed Report Decription Here :https://www.sphericalinsights.com/reports/cns-treatment-and-therapy-market    

The CNS Treatment And Therapy Market Size encompasses the research, development, production, and distribution of drugs, biologics, and advanced therapies aimed at preventing, diagnosing, and managing central nervous system disorders. These treatments focus on improving cognition, mobility, and overall patient well-being. Market growth is primarily driven by the rising prevalence of neurological conditions such as Alzheimer’s, Parkinson’s disease, epilepsy, and multiple sclerosis, along with a rapidly aging population. Lifestyle-related stress and increasing awareness of mental health issues are further elevating demand for effective CNS therapies. Additionally, ongoing advancements in drug delivery technologies, biologics, targeted treatments, minibodies, and neurostimulation approaches are accelerating innovation and expansion across the global CNS therapeutics landscape. The CNS treatment market faces challenges from high development costs, stringent regulatory approvals, and complex clinical trial requirements.

The biologics segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the drug, the CNS treatment and therapy market is divided into biologics and non biologics. Among these, the biologics segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Rising approvals of monoclonal antibodies for CNS diseases, accelerated FDA pathways, improved blood–brain barrier penetration, and personalized therapies have enhanced biologics development and increased clinical success rates.

The antidepressant segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the drug class, the CNS treatment and therapy market is divided into antidepressant, analgesics, immunomodulators, interferons, decarboxylase inhibitors, and others. Among these, the antidepressant segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Segment growth is driven by mental health awareness, reduced stigma, improved screening, and wider diagnosis, alongside increased use of safer, better-tolerated second-generation antidepressants that enhance patient adherence and treatment outcomes.

The neurovascular disease segment accounted for the largest share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the disease, the CNS treatment and therapy market is divided into neurovascular disease, degenerative disease, infectious disease, mental health, and Others. Among these, the neurovascular disease segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Segment expansion is driven by aging populations, higher hypertension and diabetes rates, and wider adoption of advanced neuro interventional therapies, supported by innovations in clot retrieval, thrombolytic agents, and cerebral protection technologies.

The hospital based pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the CNS treatment and therapy market is divided into hospital based pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital based pharmacies segment accounted for the highest market revenue in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Segment growth is supported by government hospital investments, integrated specialty services, improved inventory and adherence programs, pharmacist-led education, and strict CNS drug regulations driving reliance on compliant hospital-based pharmacy systems.

North America is expected to hold the majority share of the global CNS Treatment and Therapy market during the forecast period.

North America is expected to hold the majority share of the global CNS treatment and therapy market during the forecast period. North America is expected to dominate the CNS treatment and therapy market due to advanced healthcare infrastructure, high prevalence of neurological disorders, strong R&D investments, favorable reimbursement policies, early adoption of innovative therapies, and the presence of leading pharmaceutical and biotechnology companies.

Asia Pacific is anticipated to grow at the fastest pace in the global CNS treatment and therapy market during the forecast period. Asia Pacific is experiencing growth in the CNS treatment and therapy market due to a large patient population, rising healthcare expenditure, increasing awareness of neurological disorders, improving diagnostic capabilities, expanding pharmaceutical manufacturing, and supportive government initiatives across emerging economies.

Major vendors in the global CNS treatment and therapy market are Roche Holding AG, AbbVie Inc, GlaxoSmithKline plc, Merck & Co., Inc., AstraZeneca plc, Pfizer Inc., Johnson & Johnson, Eli Lilly, Biogen Inc, UCB S.A., Novartis AG, F. Hoffmann-La Roche Ltd, Neurocrine Biosciences, Teva Pharmaceutical Industries Ltd, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In February 2025, Boston-based Newleos Therapeutics launched with $94 million in funding from major investors, including a global bank and Novo Nordisk’s parent company. Licensed from Roche, its pipeline features four clinical-stage drugs targeting anxiety, substance use disorders, and cognitive impairment.

• In July 2024, the FDA approved Eli Lilly’s Kisunla (donanemab-azbt) for adults with early symptomatic Alzheimer’s, including MCI and mild dementia stages, with confirmed amyloid pathology. Administered monthly via IV, Kisunla is the first amyloid-targeting therapy allowing treatment cessation once plaques are cleared, potentially reducing costs and infusions.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the CNS treatment and therapy market based on the below-mentioned segments:

Global CNS Treatment and Therapy Market, By Drug

• Biologics
• Non Biologics

Global CNS Treatment and Therapy Market, By Drug Class

• Antidepressant
• Analgesics
• Immunomodulators
• Interferons
• Decarboxylase Inhibitors
• Others

Global CNS Treatment and Therapy Market, By Disease

• Neurovascular Disease
• Degenerative Disease
• Infectious Disease
• Mental Health
• Others

Global CNS Treatment and Therapy Market, By Distribution Channel

• Hospital Based Pharmacies
• Retail Pharmacies
• Online Pharmacies

 Global CNS Treatment and Therapy Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 
CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter